Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Disease Outbreaks | 24 | 2024 | 1761 | 4.240 |
Why?
|
Leptospirosis | 6 | 2024 | 45 | 2.430 |
Why?
|
Leptospira | 3 | 2024 | 25 | 1.720 |
Why?
|
Antibodies, Viral | 16 | 2024 | 3214 | 1.550 |
Why?
|
Floods | 3 | 2019 | 42 | 1.160 |
Why?
|
Hemorrhagic Fever, Ebola | 5 | 2022 | 424 | 1.120 |
Why?
|
Chikungunya virus | 2 | 2024 | 56 | 1.070 |
Why?
|
Seroepidemiologic Studies | 11 | 2024 | 404 | 1.020 |
Why?
|
Fiji | 17 | 2021 | 47 | 0.990 |
Why?
|
Dominican Republic | 4 | 2024 | 78 | 0.920 |
Why?
|
Dengue | 8 | 2021 | 258 | 0.910 |
Why?
|
Typhoid Fever | 7 | 2020 | 195 | 0.830 |
Why?
|
Trust | 2 | 2024 | 532 | 0.760 |
Why?
|
Disaster Planning | 3 | 2019 | 559 | 0.740 |
Why?
|
Diarrhea | 3 | 2017 | 1320 | 0.740 |
Why?
|
Communicable Disease Control | 4 | 2016 | 857 | 0.740 |
Why?
|
Cyclonic Storms | 3 | 2019 | 121 | 0.700 |
Why?
|
Antibodies, Bacterial | 5 | 2024 | 1478 | 0.690 |
Why?
|
Pacific Islands | 9 | 2018 | 52 | 0.690 |
Why?
|
Zoonoses | 2 | 2018 | 180 | 0.620 |
Why?
|
Rotavirus Infections | 2 | 2016 | 85 | 0.600 |
Why?
|
Rotavirus | 2 | 2016 | 110 | 0.590 |
Why?
|
Thiamine Deficiency | 1 | 2018 | 48 | 0.590 |
Why?
|
Chromium | 1 | 2018 | 133 | 0.580 |
Why?
|
El Nino-Southern Oscillation | 1 | 2017 | 2 | 0.580 |
Why?
|
Staphylococcal Skin Infections | 1 | 2018 | 78 | 0.580 |
Why?
|
Thiamine | 1 | 2018 | 160 | 0.560 |
Why?
|
Rubella Syndrome, Congenital | 1 | 2016 | 12 | 0.530 |
Why?
|
Soft Tissue Infections | 1 | 2018 | 168 | 0.520 |
Why?
|
Vitamin B Complex | 1 | 2018 | 299 | 0.510 |
Why?
|
Staphylococcal Infections | 2 | 2018 | 1398 | 0.480 |
Why?
|
Travel | 4 | 2021 | 805 | 0.470 |
Why?
|
Sentinel Surveillance | 1 | 2016 | 292 | 0.450 |
Why?
|
Tsunamis | 1 | 2014 | 61 | 0.450 |
Why?
|
Salmonella typhi | 6 | 2020 | 200 | 0.440 |
Why?
|
DNA, Bacterial | 1 | 2018 | 1478 | 0.440 |
Why?
|
Dengue Virus | 5 | 2021 | 204 | 0.430 |
Why?
|
Melanesia | 4 | 2016 | 13 | 0.420 |
Why?
|
Emergencies | 1 | 2019 | 1221 | 0.400 |
Why?
|
Plasmodium vivax | 1 | 2014 | 203 | 0.390 |
Why?
|
Public Health Practice | 1 | 2014 | 221 | 0.390 |
Why?
|
Malaria, Vivax | 1 | 2014 | 168 | 0.390 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 704 | 0.380 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 1328 | 0.370 |
Why?
|
Young Adult | 24 | 2024 | 60066 | 0.360 |
Why?
|
Health Care Rationing | 2 | 2013 | 435 | 0.360 |
Why?
|
Health Plan Implementation | 1 | 2013 | 338 | 0.350 |
Why?
|
International Cooperation | 2 | 2014 | 1436 | 0.340 |
Why?
|
Ross River virus | 2 | 2020 | 6 | 0.340 |
Why?
|
Community-Acquired Infections | 2 | 2018 | 472 | 0.340 |
Why?
|
Alphavirus Infections | 2 | 2020 | 20 | 0.340 |
Why?
|
Adolescent | 26 | 2024 | 89169 | 0.330 |
Why?
|
Typhoid-Paratyphoid Vaccines | 3 | 2020 | 40 | 0.320 |
Why?
|
Pyomyositis | 1 | 2008 | 10 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3115 | 0.310 |
Why?
|
Pneumothorax | 1 | 2012 | 393 | 0.300 |
Why?
|
Health Promotion | 3 | 2017 | 2210 | 0.290 |
Why?
|
Cerebral Hemorrhage, Traumatic | 1 | 2007 | 20 | 0.290 |
Why?
|
Humans | 76 | 2024 | 768171 | 0.290 |
Why?
|
Methicillin Resistance | 1 | 2008 | 198 | 0.290 |
Why?
|
Head Injuries, Penetrating | 1 | 2007 | 28 | 0.280 |
Why?
|
Child, Preschool | 17 | 2024 | 42669 | 0.280 |
Why?
|
Infant | 17 | 2024 | 36535 | 0.270 |
Why?
|
Climate Change | 3 | 2019 | 509 | 0.270 |
Why?
|
United Arab Emirates | 2 | 2018 | 42 | 0.270 |
Why?
|
Compartment Syndromes | 1 | 2008 | 159 | 0.260 |
Why?
|
Patient Acceptance of Health Care | 2 | 2022 | 3231 | 0.260 |
Why?
|
Immunoglobulin G | 7 | 2022 | 4568 | 0.250 |
Why?
|
Nucleocapsid | 2 | 2023 | 62 | 0.250 |
Why?
|
Primary Prevention | 1 | 2013 | 1188 | 0.250 |
Why?
|
Malaria, Falciparum | 1 | 2014 | 1077 | 0.250 |
Why?
|
Population Surveillance | 7 | 2020 | 2596 | 0.250 |
Why?
|
Guillain-Barre Syndrome | 2 | 2016 | 127 | 0.240 |
Why?
|
Micronesia | 4 | 2017 | 44 | 0.230 |
Why?
|
Plasmodium falciparum | 1 | 2014 | 1741 | 0.230 |
Why?
|
Adult | 28 | 2024 | 223646 | 0.220 |
Why?
|
Antibodies, Neutralizing | 6 | 2023 | 2009 | 0.220 |
Why?
|
Child | 20 | 2024 | 80917 | 0.210 |
Why?
|
Female | 34 | 2024 | 397187 | 0.210 |
Why?
|
Family Characteristics | 2 | 2019 | 1003 | 0.210 |
Why?
|
Public Health | 4 | 2020 | 2679 | 0.210 |
Why?
|
Cross Reactions | 2 | 2022 | 828 | 0.210 |
Why?
|
Polynesia | 3 | 2018 | 14 | 0.210 |
Why?
|
Middle Aged | 24 | 2024 | 223487 | 0.200 |
Why?
|
Male | 32 | 2024 | 364731 | 0.200 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 3814 | 0.200 |
Why?
|
Sanitation | 3 | 2017 | 83 | 0.190 |
Why?
|
Rain | 2 | 2018 | 60 | 0.190 |
Why?
|
Malaria | 1 | 2011 | 1249 | 0.190 |
Why?
|
Seasons | 5 | 2021 | 1524 | 0.190 |
Why?
|
World Health Organization | 4 | 2015 | 1328 | 0.190 |
Why?
|
Flavivirus Infections | 1 | 2021 | 16 | 0.190 |
Why?
|
Receptors, Fc | 2 | 2022 | 537 | 0.190 |
Why?
|
Wounds, Gunshot | 1 | 2007 | 587 | 0.180 |
Why?
|
Disasters | 2 | 2019 | 521 | 0.180 |
Why?
|
Immunity, Humoral | 2 | 2021 | 610 | 0.170 |
Why?
|
Staphylococcus aureus | 1 | 2008 | 1430 | 0.170 |
Why?
|
Infant, Newborn | 9 | 2021 | 26421 | 0.170 |
Why?
|
Risk Factors | 9 | 2024 | 74944 | 0.170 |
Why?
|
Congo | 1 | 2019 | 13 | 0.160 |
Why?
|
Vaccination | 5 | 2022 | 3437 | 0.160 |
Why?
|
Obesity | 1 | 2021 | 13091 | 0.160 |
Why?
|
Immunoglobulin M | 2 | 2021 | 1528 | 0.160 |
Why?
|
Space Flight | 1 | 2021 | 219 | 0.150 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26379 | 0.150 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7951 | 0.150 |
Why?
|
Phylogeny | 5 | 2019 | 2843 | 0.150 |
Why?
|
Rehydration Solutions | 1 | 2018 | 43 | 0.150 |
Why?
|
Africa, Western | 2 | 2015 | 160 | 0.150 |
Why?
|
Students, Public Health | 1 | 2017 | 6 | 0.150 |
Why?
|
Immunoassay | 1 | 2021 | 746 | 0.150 |
Why?
|
Risk Assessment | 3 | 2018 | 24318 | 0.140 |
Why?
|
Droughts | 1 | 2017 | 27 | 0.140 |
Why?
|
Health | 1 | 2020 | 398 | 0.140 |
Why?
|
Hygiene | 1 | 2017 | 95 | 0.140 |
Why?
|
Environmental Health | 1 | 2019 | 298 | 0.130 |
Why?
|
Prevalence | 4 | 2024 | 15869 | 0.130 |
Why?
|
Salmonella Infections | 1 | 2017 | 172 | 0.130 |
Why?
|
Serologic Tests | 1 | 2018 | 382 | 0.130 |
Why?
|
Aged | 14 | 2024 | 171502 | 0.130 |
Why?
|
Social Control, Formal | 2 | 2013 | 107 | 0.130 |
Why?
|
Cattle Diseases | 1 | 2016 | 50 | 0.130 |
Why?
|
Sodium Chloride | 1 | 2018 | 584 | 0.130 |
Why?
|
Fever | 1 | 2023 | 1614 | 0.120 |
Why?
|
Epidemiology | 1 | 2017 | 278 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.120 |
Why?
|
Kinetics | 1 | 2022 | 6330 | 0.120 |
Why?
|
Incidence | 6 | 2020 | 21538 | 0.120 |
Why?
|
Leprosy | 1 | 2014 | 125 | 0.110 |
Why?
|
Age Factors | 3 | 2021 | 18415 | 0.110 |
Why?
|
Cattle | 2 | 2020 | 3819 | 0.110 |
Why?
|
Fluid Therapy | 1 | 2018 | 587 | 0.110 |
Why?
|
Pandemics | 7 | 2021 | 8747 | 0.110 |
Why?
|
Papua New Guinea | 1 | 2013 | 47 | 0.110 |
Why?
|
Epidemics | 2 | 2021 | 517 | 0.110 |
Why?
|
Phosphoproteins | 1 | 2022 | 2451 | 0.110 |
Why?
|
Lung | 1 | 2012 | 10101 | 0.110 |
Why?
|
Polymerase Chain Reaction | 2 | 2022 | 6082 | 0.110 |
Why?
|
Communicable Diseases | 1 | 2021 | 873 | 0.100 |
Why?
|
Case-Control Studies | 4 | 2018 | 22290 | 0.100 |
Why?
|
Capsid Proteins | 1 | 2016 | 468 | 0.100 |
Why?
|
Disease Transmission, Infectious | 1 | 2018 | 560 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3238 | 0.100 |
Why?
|
Gastroenteritis | 1 | 2014 | 235 | 0.100 |
Why?
|
Sports | 1 | 2018 | 703 | 0.100 |
Why?
|
Antigens, Viral | 1 | 2016 | 995 | 0.100 |
Why?
|
Altitude Sickness | 1 | 2012 | 93 | 0.100 |
Why?
|
Preventive Health Services | 2 | 2013 | 570 | 0.090 |
Why?
|
Ecosystem | 1 | 2016 | 494 | 0.090 |
Why?
|
Logistic Models | 4 | 2022 | 13290 | 0.090 |
Why?
|
Democratic Republic of the Congo | 2 | 2022 | 87 | 0.090 |
Why?
|
Maternal Exposure | 1 | 2018 | 1096 | 0.090 |
Why?
|
Polysaccharides, Bacterial | 1 | 2014 | 582 | 0.090 |
Why?
|
Social Behavior | 1 | 2017 | 1147 | 0.090 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2018 | 1027 | 0.090 |
Why?
|
Eating | 1 | 2017 | 1542 | 0.090 |
Why?
|
Sensitivity and Specificity | 3 | 2021 | 14729 | 0.090 |
Why?
|
Respiratory Tract Infections | 1 | 2018 | 1014 | 0.090 |
Why?
|
Information Dissemination | 1 | 2019 | 1143 | 0.090 |
Why?
|
Health Behavior | 1 | 2022 | 2650 | 0.090 |
Why?
|
Environment | 1 | 2016 | 1121 | 0.080 |
Why?
|
Commerce | 1 | 2015 | 612 | 0.080 |
Why?
|
Aedes | 3 | 2014 | 101 | 0.080 |
Why?
|
Multiple Trauma | 1 | 2012 | 369 | 0.080 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2012 | 418 | 0.080 |
Why?
|
Animals | 11 | 2024 | 169285 | 0.080 |
Why?
|
Sex Factors | 2 | 2022 | 10632 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2012 | 990 | 0.070 |
Why?
|
Models, Theoretical | 2 | 2018 | 3573 | 0.070 |
Why?
|
Viral Proteins | 1 | 2014 | 1802 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12077 | 0.070 |
Why?
|
Environmental Exposure | 2 | 2019 | 4543 | 0.070 |
Why?
|
Child Development | 1 | 2018 | 2330 | 0.070 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2018 | 2185 | 0.070 |
Why?
|
Accidents, Traffic | 1 | 2012 | 818 | 0.070 |
Why?
|
Hospitalization | 2 | 2018 | 10840 | 0.070 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2018 | 2539 | 0.060 |
Why?
|
Forearm | 1 | 2008 | 427 | 0.060 |
Why?
|
Acute Disease | 2 | 2018 | 7243 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7852 | 0.060 |
Why?
|
Influenza Vaccines | 1 | 2013 | 781 | 0.060 |
Why?
|
Radiography, Thoracic | 1 | 2012 | 1321 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2018 | 59626 | 0.060 |
Why?
|
Prospective Studies | 3 | 2022 | 54924 | 0.060 |
Why?
|
Antimalarials | 1 | 2011 | 909 | 0.060 |
Why?
|
Communication | 1 | 2019 | 3905 | 0.060 |
Why?
|
Australia | 2 | 2021 | 1265 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2021 | 81760 | 0.060 |
Why?
|
Anti-Bacterial Agents | 3 | 2018 | 7477 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4055 | 0.060 |
Why?
|
Body Mass Index | 1 | 2021 | 13053 | 0.060 |
Why?
|
Models, Statistical | 1 | 2018 | 5107 | 0.050 |
Why?
|
Disease Management | 1 | 2014 | 2535 | 0.050 |
Why?
|
History, 21st Century | 2 | 2020 | 1573 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5367 | 0.050 |
Why?
|
Rural Population | 3 | 2018 | 2325 | 0.050 |
Why?
|
Time Factors | 3 | 2022 | 40220 | 0.050 |
Why?
|
Coronavirus OC43, Human | 1 | 2021 | 20 | 0.050 |
Why?
|
Influenza, Human | 1 | 2013 | 1541 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1605 | 0.050 |
Why?
|
Flavivirus | 1 | 2021 | 23 | 0.050 |
Why?
|
Sequence Analysis, DNA | 3 | 2019 | 4786 | 0.050 |
Why?
|
Samoa | 1 | 2020 | 5 | 0.050 |
Why?
|
Culicidae | 1 | 2021 | 111 | 0.040 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2023 | 414 | 0.040 |
Why?
|
Marsupialia | 1 | 2020 | 21 | 0.040 |
Why?
|
Pregnancy | 4 | 2020 | 30255 | 0.040 |
Why?
|
Odds Ratio | 3 | 2018 | 9669 | 0.040 |
Why?
|
Asymptomatic Infections | 1 | 2021 | 136 | 0.040 |
Why?
|
Goats | 1 | 2020 | 166 | 0.040 |
Why?
|
Immunoglobulin Class Switching | 1 | 2021 | 289 | 0.040 |
Why?
|
Neutralization Tests | 1 | 2022 | 739 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2011 | 1947 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 622 | 0.040 |
Why?
|
Horses | 1 | 2020 | 295 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2018 | 2732 | 0.040 |
Why?
|
Livestock | 1 | 2018 | 20 | 0.040 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 334 | 0.040 |
Why?
|
Ethiopia | 1 | 2020 | 485 | 0.040 |
Why?
|
Animal Husbandry | 1 | 2018 | 64 | 0.040 |
Why?
|
Immunity, Herd | 1 | 2018 | 48 | 0.040 |
Why?
|
Animals, Domestic | 1 | 2017 | 56 | 0.040 |
Why?
|
Environmental Microbiology | 1 | 2018 | 47 | 0.040 |
Why?
|
Government Programs | 1 | 2020 | 278 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2021 | 992 | 0.040 |
Why?
|
Carrier State | 1 | 2021 | 529 | 0.030 |
Why?
|
Agriculture | 1 | 2018 | 186 | 0.030 |
Why?
|
Poverty | 2 | 2018 | 2720 | 0.030 |
Why?
|
Radiography | 1 | 2007 | 6986 | 0.030 |
Why?
|
Peptides, Cyclic | 1 | 2018 | 391 | 0.030 |
Why?
|
Viral Envelope Proteins | 1 | 2019 | 640 | 0.030 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2021 | 596 | 0.030 |
Why?
|
Workplace | 1 | 2022 | 873 | 0.030 |
Why?
|
Phylogeography | 1 | 2015 | 72 | 0.030 |
Why?
|
Contact Tracing | 1 | 2017 | 275 | 0.030 |
Why?
|
Ownership | 1 | 2017 | 338 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2022 | 2363 | 0.030 |
Why?
|
Dogs | 1 | 2020 | 3845 | 0.030 |
Why?
|
Infectious Disease Incubation Period | 1 | 2014 | 16 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
New Caledonia | 1 | 2014 | 3 | 0.030 |
Why?
|
Mycobacterium leprae | 1 | 2014 | 95 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2020 | 942 | 0.030 |
Why?
|
Disease Vectors | 1 | 2014 | 61 | 0.030 |
Why?
|
Salmonella enterica | 1 | 2014 | 75 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3346 | 0.030 |
Why?
|
Population Density | 1 | 2014 | 193 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2018 | 703 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2016 | 914 | 0.030 |
Why?
|
Self Efficacy | 1 | 2017 | 643 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2230 | 0.030 |
Why?
|
Host-Pathogen Interactions | 1 | 2022 | 1469 | 0.030 |
Why?
|
Viral Nonstructural Proteins | 1 | 2014 | 228 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 13013 | 0.030 |
Why?
|
Communicable Diseases, Emerging | 1 | 2014 | 148 | 0.030 |
Why?
|
Mountaineering | 1 | 2012 | 45 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1641 | 0.030 |
Why?
|
Ciprofloxacin | 1 | 2014 | 313 | 0.030 |
Why?
|
Acetazolamide | 1 | 2012 | 98 | 0.030 |
Why?
|
Nifedipine | 1 | 2012 | 220 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2278 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2018 | 1443 | 0.020 |
Why?
|
Ebolavirus | 1 | 2014 | 250 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2015 | 17623 | 0.020 |
Why?
|
Molecular Epidemiology | 1 | 2014 | 473 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15949 | 0.020 |
Why?
|
Nepal | 1 | 2012 | 301 | 0.020 |
Why?
|
Age Distribution | 1 | 2017 | 2873 | 0.020 |
Why?
|
Survivors | 1 | 2021 | 2381 | 0.020 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2015 | 591 | 0.020 |
Why?
|
Urban Population | 1 | 2018 | 2046 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2359 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2017 | 1434 | 0.020 |
Why?
|
Genome, Bacterial | 1 | 2015 | 796 | 0.020 |
Why?
|
Sulfones | 1 | 2012 | 448 | 0.020 |
Why?
|
Swine | 1 | 2020 | 5997 | 0.020 |
Why?
|
Quinolines | 1 | 2015 | 772 | 0.020 |
Why?
|
Protein Binding | 1 | 2022 | 9343 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2014 | 812 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5315 | 0.020 |
Why?
|
Purines | 1 | 2012 | 615 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2507 | 0.020 |
Why?
|
Emergency Treatment | 1 | 2012 | 497 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2014 | 2923 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41753 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10099 | 0.020 |
Why?
|
United States | 3 | 2022 | 73039 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2014 | 1896 | 0.020 |
Why?
|
RNA, Viral | 1 | 2014 | 2874 | 0.020 |
Why?
|
Dexamethasone | 1 | 2012 | 1965 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2012 | 65379 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13668 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8741 | 0.010 |
Why?
|
Curriculum | 1 | 2017 | 3782 | 0.010 |
Why?
|
Rats | 1 | 2020 | 23782 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10266 | 0.010 |
Why?
|
Mortality | 1 | 2014 | 2911 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20225 | 0.010 |
Why?
|
Piperazines | 1 | 2012 | 2554 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 13045 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7454 | 0.010 |
Why?
|
Mice | 1 | 2020 | 82049 | 0.010 |
Why?
|
Concepts
(303)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(55)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_